Ryeqo drug is hailed as a ‘potential step-change’ in how endometriosis is treated A new pill designed to transform the treatment of endometriosis has been approved for use on the NHS in ...

The new tablet, known as Ryeqo or relugolix-estradiol-norethisterone, has been approved to treat women of reproductive age for whom other treatment options – including medical and surgical ...

Ryeqo was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) last October based on results from the LIBERTY programme, consisting of two 24-week phase 3 clinical trials.

Relugolix–estradiol–norethisterone (Ryeqo) is available on the NHS. It is a possible treatment for symptoms of endometriosis in adults of reproductive age who have had medical or surgical treatment ...

Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy after Gedeon Richter's Ryeqo was cleared for NHS use. This morning, NICE recommended ...

The drug - known as relugolix combination therapy or Ryeqo - was approved by the National Institute for Health and Care Excellence (NICE) for NHS use. This is the first long-term daily pill ...